# European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)

Source: https://onco.cc/key-papers/paper-eau-nmibc-guideline-eur-urol-2022/  
OnCo record `paper-eau-nmibc-guideline-eur-urol-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The European urology guideline sets out how to diagnose, resect, risk-group and treat bladder cancers that have not reached the muscle, including when BCG is needed and when to remove the bladder.

## Summary

Evidence-based guideline from the European Association of Urology covering diagnosis, transurethral resection, re-resection, risk stratification, intravesical chemotherapy and BCG, management of BCG failure, and follow-up for non-muscle-invasive bladder cancer.

It introduces the 2021 EAU risk groups with a very-high-risk category for which early radical cystectomy is recommended, and defines BCG-unresponsive disease for trial and treatment purposes.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: European Urology
- Year: 2022
- DOI: 10.1016/j.eururo.2021.08.010
- Authors: Babjuk M, Burger M, Capoun O, et al.
- What it means: Most of the decisions on a non-muscle-invasive bladder cancer page (single instillation, BCG maintenance, early cystectomy, bladder-sparing trials) follow this guideline or its American counterpart.
- Caveats: Updated yearly; check the current edition for the latest recommendations on new bladder-sparing agents.

## Sources

- Eur Urol 2022: https://doi.org/10.1016/j.eururo.2021.08.010
- PubMed: https://pubmed.ncbi.nlm.nih.gov/34511303/

## Connected records

- cancers: [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/)
- journals: [European Urology](https://onco.cc/journals/european-urology/)

---
JSON: https://onco.cc/api/v1/entities/paper-eau-nmibc-guideline-eur-urol-2022.json